Testing the implementation and sustainment facilitation (ISF) strategy as an effective adjunct to the Addiction Technology Transfer Center (ATTC) strategy: study protocol for a cluster randomized trial

摘要: Improving the extent to which evidence-based practices (EBPs)—treatments that have been empirically shown be efficacious or effective—are integrated within routine practice is a well-documented challenge across numerous areas of health. In 2014, National Institute on Drug Abuse funded type 2 effectiveness–implementation hybrid trial titled substance abuse treatment HIV Care (SAT2HIV) Project. Aim 1 SAT2HIV Project tests effectiveness motivational interviewing-based brief intervention (MIBI) for use as an adjunct usual care AIDS service organizations (ASOs) part its MIBI Experiment. implementation and sustainment facilitation (ISF) Addiction Technology Transfer Center (ATTC) model training staff in interviewing ISF The current paper describes study protocol Experiment. Using cluster randomized design, case management leadership from 39 ASOs United States were receive either ATTC strategy (control condition) ATTC + ISF (experimental condition). staff-focused includes 10 discrete strategies (e.g., provide centralized technical assistance, conduct educational meetings, ongoing consultation). organization-focused seven advisor, organize team cyclical small change). Building upon exploration–preparation–implementation–sustainment (EPIS) framework, examined via three staff-level measures: (1) time-to-proficiency (i.e., preparation phase outcome), (2) (3) level outcome). Although not without limitations, experiment has several strengths: highly rigorous design (randomized, hypothesis-driven), high-need setting (ASOs), large sample size (39 ASOs), geographic representation (23 states District Columbia), testing along multiple phases EPIS continuum (preparation, implementation, sustainment). Thus, findings will significantly improve generalizable knowledge regarding best preparation, advancing EBPs continuum. Moreover, increasing ASO’s capacity address may Continuum. Trial registration ClinicalTrials.gov: NCT03120598.